Abstracts differences in negative values could be the result of cultural differences or due to small differences in the operationalization of TTO. CONCLUSION: The differences in the value of health between the European countries seem to be small. This opens the door for a European tariff for the EQ-5D, which might facilitate QALY-analysis in international trials considerably.
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Determining the best method for cost analysis of end-oflife care regimens requires a systematic approach for connecting the research question being addressed with the data requirements and analyses. There are several guiding principles to direct this research, specifically in the areas of sensitivity analysis, uncertainty, generalizability, and measurement of efficiency such as cost-benefit or costutility. There exists a body of literature in which diseasespecific or system-wide costing of health care is described, but few apply to end-of-life care. OBJECTIVE: To investigate, evaluate and present costanalysis methods through a synthesis of recently published literature, and the implications of applying these methods to ongoing clinical studies. METHODS: Cost analyses include those acquired from articles published in professional journals in the area of cost, cost analysis and end-of-life care and applied to a set of on-going clinical studies. RESULTS: Based on a sample of nearly 30,000 cost studies in which few consider end-of-life care, at least eight methods for examining costs of care are defined. On one end of the spectrum is the micro-costing method in which all personnel time, supplies, cost of facilities, pharmaceuticals, lab expenses and all other patient services conducted are tracked and costed using a variety of codes. On the other end is the attributable costing method that uses aggregate and average costs for inpatient and outpatient care as well as for procedures and drugs associated with the corresponding diagnosis and treatment. Only newly initiated studies can feasibly employ micro costing. On-going studies require abstracting from other methods. CONCLUSIONS: In light of the national concern over costs associated with end-of-life care, efforts are needed to amalgamate guidelines and methodologies in this area in order to provide a useful and accessible resource to conduct meaningful cost-analysis research.
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VALUATION OF INFORMAL CARE van den Berg B Erasmus University Rotterdam, Rotterdam, Netherlands
OBJECTIVES:
The aim of our research has been the valuation of informal care. Informal care plays a substantial role in the total care provided to patients with chronic diseases. However, at this moment informal care is hardly incorporated in economic evaluations of health care. Especially the combination of the costs (time invested and household expenditures) and effects (health-related quality of life of informal care giving) is innovative. METHODS: The data were collected by mailed questionnaires to primary informal caregivers in an evaluation of Dutch integrated stroke service experiments, at two moments in time. The sample size is 217 informal caregivers (two months after stroke) and 158 caregivers (six months after stroke). We used a questionnaire including a range of items on different informal care tasks. Health related quality of life was measured with the EuroQol (EQ#64979; 5).
RESULTS:
Two months after stroke informal caregivers spent 22.7 hours a week (mean) on a range of different care tasks. Six months after stroke they spent 25.1 hours a week (mean) on the same tasks. Their mean EQ-5 score is 0.836 (n ϭ 195) after two months and 0.816 (n ϭ 138) after six months. After two months 40 percent reports pain and other complaints and 25 percent reports anxiety. Six months after stroke this is respective 45 percent and 25 percent. Health related quality of life results and time invested will be compared to the general population by sex and age. Current cost-effectiveness models of antibiotic efficacy typically do not consider the variability in relative incidence of infectious agents or the probability of speciesspecific antibiotic resistance. A model that incorporates this variability in incidence and resistance will more accurately represent epidemiological variances and associated differences in treatment costs across patient populations. OBJECTIVES: To create a model of antibiotic efficacy that generates population-specific cost-effectiveness ratios by including incidence and resistance rates of infectious agents and can be adjusted to reflect epidemiological data specific to different geographic regions.
METHODS:
We constructed a decision tree model that represents a user-defined infection (i.e. acute exacerbation of chronic bronchitis). This model considers the relative incidence of infectious agents (bacterial and nonbacterial/viral), the incidence of resistance among the bacteria agents, and antibiotic efficacy against each infectious agent and level of resistance. The model can represent "all-or-none" resistance such as that associated with beta-lactamase production, or varying degrees of susceptibility associated with other methods of resistance. The model can represent clinical or in vitro efficacy, depending on the source of the data. In the event of insufficient data to populate the resistance branch, this branch can be collapsed out of the tree. The model will then represent antibiotic efficacy for all infectious agents included. RESULTS: The model generates cost-effectiveness ratios identifying conditions where the antibiotic of interest is cost effective or cost saving versus other antibiotics. Ratios for individual infectious agents and levels of resistance also identify specific populations where the antibiotic of interest has an advantage. CONCLUSIONS: This model can incorporate geographic diversity of and resistance in bacterial populations to generate cost-effectiveness ratios specific to different epidemiological and geographic populations. 
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COST-EFFECTIVENESS OF TUBERCULOSIS PREVENTIVE THERAPY IN HIV-INFECTED PATIENTS: STUDY OF MISSING VARIABLES
